BioSpace News Archive

The FDA amended its EUA for GlaxoSmithKline and Vir Biotechnology’s sotrovimab for COVID-19. The amendment relates specifically to the BA.2 Omicron sub-variant.

AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.

Before cell and gene therapy can truly become mainstream medicine, the challenges of allogeneic rejection and targeted delivery must be solved. Sana Biotechnology is on the path to do that.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

Per Bloomberg: Singapore-based Temask Holdings is calling for the installation of a new chief executive officer at Bayer.

The FDA released materials for review ahead of Wednesday’s meeting and it appears to paint a picture of insufficient data for approval, noting it is “not exceptionally persuasive.”

Typically occurring after sufferers regain their total smell loss from anosmia, parosmia is an olfactory disorder that causes smell distortions.

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the definitive notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported data published in the peer reviewed International Journal of Molecular Sciences, indicating that prolonged release of amino acids formulated with APR’s PhysiomimicTM Technology may have benefits for the dietary management of phenylketonuria.

Galapagos NV reports that Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced the approval by the Japanese Ministry of Health, Labour and Welfare, of a second indication for Jyseleca, a once-daily, oral, JAK1 preferentialinhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis.